Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer.
Matthew P GoetzErika Paige HamiltonMario CamponeSara Alsterlind HurvitzJavier CortesStephen R D JohnstonAntonio LlombartPeter A KaufmanMasakazu ToiGuy JerusalemHillary GrahamHong WangValerie M JansenLacey M LitchfieldMiguel MartinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
In MONARCH 3, certain baseline ctDNA genomic alterations were prognostic for ET but not predictive of abemaciclib response. Further studies are warranted to assess whether ctDNA alterations acquired during abemaciclib treatment differ from other CDK4/6 inhibitors. Findings are hypothesis-generating, further exploration is warranted into mechanisms of resistance to abemaciclib and ET.